Delta-Fly Pharma, Inc.

4598

JP3549370009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
778 ^JPY	-2.87%		-3.35%	-23.35%

Apr. 08	Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	CI
Mar. 11	Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	CI

Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited

December 04, 2022

On December 5, 2022, Delta-Fly Pharma, Inc. closed the transaction.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	DELTA-FLY PHARMA, INC.	778 JPY	-2.87%	-3.35%	40.67M
	MACQUARIE GROUP LIMITED	187.6 AUD	+0.64%	+0.54%	44.31B

Latest news about Delta-Fly Pharma, Inc.

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	Apr. 08	CI
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	Mar. 11	CI
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	Feb. 07	CI
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	Feb. 02	CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	Jan. 30	CI
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.	Nov. 09	CI
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited	22-12-04	CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ã‘1.300842 billion in funding from Macquarie Group Limited	22-11-16	CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	20-12-23	CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	20-12-07	CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa	20-03-23	CI
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927	19-11-26	CI
Certain Common Shares of Delta-Fly Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019.	19-01-08	CI
Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion.	18-10-11	CI
Delta-Fly Pharma, Inc. has filed an IPO.	18-09-05	CI
Delta-Fly Pharma, Inc. announced that it has received funding from Sanyo Chemical Industries Ltd.	18-03-22	CI

Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
DELTA-FLY PHARMA, INC.	-23.35%	40.67M
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B

Other Pharmaceuticals